Kimberly-Clark Corporation (KMB)vsSanofi ADR (SNY)
KMB
Kimberly-Clark Corporation
$98.31
-1.26%
CONSUMER DEFENSIVE · Cap: $33.05B
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 186% more annual revenue ($47.35B vs $16.56B). SNY leads profitability with a 16.0% profit margin vs 12.8%. KMB appears more attractively valued with a PEG of 2.00. KMB earns a higher WallStSmart Score of 61/100 (C+).
KMB
Buy61
out of 100
Grade: C+
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-18.9%
Fair Value
$90.52
Current Price
$98.31
$7.79 premium
Margin of Safety
+24.9%
Fair Value
$62.64
Current Price
$43.31
$19.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 112 in profit
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 18.2x book value
2.7% revenue growth
Weak financial health signals
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : KMB
The strongest argument for KMB centers on Return on Equity.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : KMB
The primary concerns for KMB are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 4.77 is elevated, increasing financial risk.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
KMB profiles as a value stock while SNY is a mature play — different risk/reward profiles.
KMB carries more volatility with a beta of 0.31 — expect wider price swings.
SNY is growing revenue faster at 6.0% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
KMB scores higher overall (61/100 vs 51/100). SNY offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kimberly-Clark Corporation
CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA
Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.
Visit Website →Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other HOUSEHOLD & PERSONAL PRODUCTS Stocks
Want to dig deeper into these stocks?